Engineered immune cells take on tough T-Cell cancers

NCT ID NCT06316856

Recruiting now Disease control Sponsor: Beijing GoBroad Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times

Summary

This study tests a new treatment called CD5 CAR-T cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells (or cells from a donor) that are specially trained to find and attack cancer cells. The goal is to see if it is safe and effective, with 54 participants enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing GoBroad Hospital
RECRUITING

Beijing, Beijing Municipality, 102206, China
Shanghai Liquan Hospital
RECRUITING

Shanghai, Shanghai Municipality, 201418, China
The General Hospital of Western Theater Command PLA
NOT_YET_RECRUITING

Chengdu, Sichuan, 610083, China
Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai
RECRUITING

Shanghai, Shanghai Municipality, 200435, China

Conditions

Explore the condition pages connected to this study.

ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA T-CELL ACUTE LYMPHOCYTIC LEUKEMIA T-CELL ACUTE LYMPHOCYTIC LEUKEMIA T-CELL MALIGNANCIES T-CELL MALIGNANCIES